SRPT

Duchenne Muscular Dystrophy and Rare Disease Patient Access to Treatments Newborn Screening for Rare Diseases Scientific Innovation in Healthcare Gene Therapies Artificial Intelligence and Data Governance

Scientific innovation in healthcare including gene therapy, rare diseases including Duchenne muscular dystrophy Scientific innovation in healthcare including gene therapy, rare diseases including Duchenne muscular dystrophy

federal budget issues innovation, Duchenne Muscular Dystrophy, platform technologies, value based contracting, gene therapy Medicaid drug rebate program, coverage, state program operations, waivers, gene therapy, value based contracting

Patient Access to Treatments Newborn Screening for Rare Diseases Scientific Innovation in Healthcare Gene Therapies Rare Diseases Artificial Intelligence and Data Governance

Scientific innovation in healthcare including gene therapy, rare diseases including Duchenne muscular dystrophy Scientific innovation in healthcare including gene therapy, rare diseases including Duchenne muscular dystrophy

federal budget issues innovation, Duchenne Muscular Dystrophy, platform technologies, value based contracting, gene therapy Medicaid drug rebate program, coverage, state program operations, waivers, gene therapy, value based contracting

Scientific innovation in healthcare including gene therapy, rare diseases including Duchenne muscular dystrophy Scientific innovation in healthcare including gene therapy, rare diseases including Duchenne muscular dystrophy

federal budget issues innovation, Duchenne Muscular Dystrophy, platform technologies, value based contracting, gene therapy Medicaid drug rebate program, coverage, state program operations, waivers, gene therapy, value based contracting, Medicaid value based payment rule

Issues related to patient access to treatments Issues related to rare diseases such as Duchenne Muscular Dystrophy Issues related to newborn screening for rare diseases Issues related to the Inflation Reduction Act's prescription drug provisions Issues related to scientific innovation in healthcare such as gene therapies Issues related to artificial intelligence and data governance Tax issues related to research and development

federal budget issues innovation, Duchenne Muscular Dystrophy, platform technologies, value based contracting, gene therapy Medicaid drug rebate program, coverage, state program operations, waivers, gene therapy, value based contracting, Medicaid value based payment rule